CoChat

A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment: The TRIMCI Study

Gómez-Isla, Teresa, Blesa, Rafael, Boada, Merce, Clarimón, Jordi, Ser, Teodoro Del, Domenech, Gemma, Ferro, Jose M., Gómez-Ansón, Beatriz, Manubens, Jose M., Martínez-Lage, Jose M., Muñoz, David, Peña-Casanova, Jordi, Torres, Ferran · 2008 · Alzheimer Disease & Associated Disorders
Cited by 64

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Amnestic mild cognitive impairment represents, in many cases, the earliest clinical phases of Alzheimer disease. Anti-inflammatory agents have epidemiologic support as drugs potentially beneficial in Alzheimer disease. In vivo studies have shown that Triflusal and its active metabolite 2-hydroxy-4-trifluoromethyl-benzoic acid have potent anti-inflammatory actions in the central nervous system. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of Triflusal in patients with amnestic mild cognitive impairment. Subjects were randomly assigned to receive 900 mg of Triflusal or placebo for 18 months. The primary outcome was a change in Cognitive subscale of the Alzheimer Disease Assessment Scale; conversion to dementia was a secondary outcome. RESULTS: A slow rate of recruitment forced a premature cessation of the study. Two hundred and fifty-seven subjects were enrolled and followed-up for an average of 13 months. The significance level was not reached for the primary outcome even though a trend in favor of Triflusal was observed. However, there was a significant difference in the probability of progression to dementia of Alzheimer's type with a lower risk in the Triflusal compared with the placebo group (hazard ratio, 2.10; 95% confidence interval, 1.10-4.01; P=0.024). CONCLUSIONS: In this study, Triflusal therapy was associated with a significant lower rate of conversion to dementia that is likely to be clinically relevant. Because the trial was prematurely halted, these results should be interpreted with caution and require further confirmation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wad.0b013e3181611024

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 64

Metadata

Authors
Gómez-Isla, T., Blesa, R., Boada, M., Clarimón, J., Ser, T. D., Domenech, G., Ferro, J. M., Gómez-Ansón, B., Manubens, J. M., Martínez-Lage, J. M., Muñoz, D., Peña-Casanova, J., & Torres, F.
Venue
Alzheimer Disease & Associated Disorders
Published
2008-01
Volume
22
Issue
1
Pages
21-29
ISSN
0893-0341 (ISSN-L)
OpenAlex
W1992318681
Cited by
64
References
8
FWCI
3.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment: The TRIMCI Study. https://app.cochat.ai/papers/10.1097/wad.0b013e3181611024
The paper
Gómez-Isla, T., Blesa, R., Boada, M., Clarimón, J., Ser, T. D., Domenech, G., Ferro, J. M., Gómez-Ansón, B., Manubens, J. M., Martínez-Lage, J. M., Muñoz, D., Peña-Casanova, J., & Torres, F. (2008). A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment: The TRIMCI Study. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/wad.0b013e3181611024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.